Product Description
Mechanisms of Action: 5-HT2A Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Insomnia
Phase 2: Fibromyalgia|Chronic Pain|Myofascial Pain Syndromes|Parasomnias
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2014-004644-35 | P1 |
Terminated |
Insomnia |
2013-02-25 |
|
PKiDs | P1 |
Completed |
Insomnia |
2009-12-01 |
|
ECLIPSE | P3 |
Completed |
Insomnia |
2009-06-05 |
|
ECLIPSE | P3 |
Completed |
Insomnia |
2009-06-01 |